# Affordable-Drug-Alternatives

| Drug | Drug_Price| DrugSubstitute| DrugSubstitute_Price | Condition | Condition_Prevalence | GeographicalRegion |
|------|-----------|---------------|----------------------|-----------|----------------------|--------------------|
|Esketamine (Spravato®)|US list (no insurance): $590 – $885 per 56–84 mg session. Induction month (8 sessions): ≈ $4,720 – $7,080|Ketamine (racemic, IV infusion)|US cash-pay: $300 – $1,000 per infusion. Typical 6–8-session induction: ≈ $2,100 – $6,000|Treatment-Resistant Depression (TRD)|MDD patients who fail ≥2 adequate antidepressant trials; prevalence ≈ 30 – 40 % in the general U.S. MDD population (claims-based PTD rate ≈ 6 %)|United States|

# Head-to-Head: Esketamine vs. Ketamine
<p align="center">
  <img src="https://github.com/user-attachments/assets/700f5f30-ecaa-4265-910e-afee107310ae" width="600">
</p>


